Abbott Laboratories (ABT) Stock Forecast & Price Target

$119.39

+1.50 (+1.27%)

(As of 10/18/2024 ET)

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, and 12 have given a buy rating for ABT.

Consensus Price Target

$129.67
8.61% Upside

According to the 16 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $129.67. The highest price target for ABT is $146.00, while the lowest price target for ABT is $117.00. The average price target represents a forecasted upside of 8.61% from the current price of $119.39.

ABT Analyst Ratings Over Time

Type	Current Forecast 10/21/23 to 10/20/24	1 Month Ago 9/21/23 to 9/20/24	3 Months Ago 7/23/23 to 7/22/24	1 Year Ago 10/21/22 to 10/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$129.67	$123.33	$120.70	$117.47
Forecasted Upside	8.61% Upside	8.48% Upside	16.35% Upside	21.37% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Have you heard of Donald Trump’s Project Crypto? (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Learn More Here

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	8.61% Upside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/17/2024	Sanford C. Bernstein 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/17/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$143.00 ➝ $146.00	+24.14%
10/17/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Hold ➝ Hold	$120.00 ➝ $125.00	+5.91%
10/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$115.00 ➝ $130.00	+10.34%
10/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $117.00	-0.70%
10/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$131.00 ➝ $133.00	+12.88%
Have you heard of Donald Trump’s Project Crypto? (Ad) Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.” Learn More Here
10/14/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Buy	$122.00 ➝ $129.00	+10.28%
10/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$125.00 ➝ $130.00	+13.33%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$120.00 ➝ $124.00	+8.87%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$119.00 ➝ $127.00	+13.95%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$140.00 ➝ $143.00	+37.90%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$121.00	+20.11%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$116.00 ➝ $121.00	+13.70%
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Peer Perform
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $130.00	+25.05%
3/31/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$90.00 ➝ $102.00	+2.95%
3/30/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $115.00	+16.61%
1/26/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$110.00 ➝ $125.00	+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:42 AM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 13, 2024. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
The company has a diversified product portfolio across healthcare segments, reducing risk associated with dependence on a single product.
Abbott Laboratories has a solid track record of dividend payments, providing investors with a reliable income stream.
Recent analyst price targets suggest a positive outlook for the stock, indicating potential for capital appreciation.
With a current stock price of $115.62, Abbott Laboratories offers a stable investment opportunity with room for growth.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Abbott Laboratories operates in a highly regulated industry, subject to potential changes in healthcare policies that could impact profitability.
The company faces competition from other healthcare giants, which may limit market share growth and pricing power.
Fluctuations in currency exchange rates could affect Abbott Laboratories' international operations and financial results.
Investors should consider the company's debt-to-equity ratio of 0.33, which may indicate higher financial leverage and associated risks.
While the PEG ratio of 2.86 suggests growth potential, investors should be cautious of potential overvaluation in the stock.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $129.67, with a high forecast of $146.00 and a low forecast of $117.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 8.61% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 1 downgrade by analysts.
: Abbott Laboratories has been rated by research analysts at Barclays, Citigroup, Edward Jones, Evercore ISI, Jefferies Financial Group, Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Piper Sandler Companies, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and UBS Group in the past 90 days.
: Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.75 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Have you heard of Donald Trump’s Project Crypto? (Ad)

Learn More Here

This page (NYSE:ABT) was last updated on 10/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Abbott Laboratories (ABT) Stock Forecast & Price Target